仙乐健康科技股份有限公司 内部审计管理制度 第一章 总 则 第一条 为加强和规范仙乐健康科技股份有限公司（以下简称"公司"）的内 部审计工作，加强内部控制管理，防范和控制公司风险，保障公司及股东的合法 权益，依据《中华人民共和国公司法》、《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》、《中华人民共和国审计法》、《审计署关于 内部审计工作的规定》、《企业内部控制基本规范》等法律法规以及《仙乐健康科 技股份有限公司章程》（以下简称"章程"），结合公司实际情况，制定本制度。 第二条 本制度适用于公司各内部机构、全资及控股子公司、分公司以及具 有重大影响的参股公司。 第三条 本制度所涉内部审计是指内部审计部门或审计人员对本公司及各下 属单位内部控制、财务状况、资产质量、经营绩效、重大项目等经济活动的真实 性、合法性和效益性进行监督、评价和建议的活动。本制度所涉审计对象特指公 司及其全资或控股子公司、分公司、具有重大影响的参股公司，以及公司各内部 机构和上述子公司的相关责任人员。 第四条 内部审计基本原则： 独立性原则：审计部独立行使职权，不受其他部门或人员干预，确保审计工 作的独立性和权 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 954,215,143.94, representing a slight increase of 0.28% compared to CNY 951,504,195.36 in the same period last year[3]. - Net profit attributable to shareholders increased by 8.90% to CNY 68,640,679.60 from CNY 63,029,722.56 year-on-year[3]. - The company's basic earnings per share rose by 9.55% to CNY 0.2926 from CNY 0.2671 in the same period last year[3]. - Net profit for the current period was ¥56,487,064.91, compared to ¥53,871,136.53 in the previous period, representing an increase of approximately 3.0%[29]. - The net profit attributable to the parent company was ¥68,640,679.60, up from ¥63,029,722.56, indicating a growth of around 8.5%[29]. - Basic and diluted earnings per share improved to ¥0.2926 from ¥0.2671, showing an increase of about 9.9%[30]. Cash Flow - The net cash flow from operating activities improved significantly to CNY 63,522,487.01, compared to a negative cash flow of CNY -72,301,258.02 in the previous year[8]. - Cash flow from operating activities was ¥1,167,076,628.12, compared to ¥918,338,578.40 in the previous period, indicating a significant increase in cash inflow[32]. - Net cash flow from operating activities was $63.52 million, a significant improvement from a net outflow of $72.30 million in the previous period[33]. - The ending balance of cash and cash equivalents was $589.48 million, compared to $403.85 million at the end of the previous year[33]. - Cash inflow from operating activities amounted to $1.19 billion, an increase from $928.32 million year-over-year[33]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 5,614,182,320.66, up 2.34% from CNY 5,486,023,079.85 at the end of the previous year[3]. - The total liabilities increased to ¥2,899,981,514.55 from ¥2,844,825,104.64, reflecting a rise of about 1.9%[27]. - Total equity attributable to the parent company rose to ¥2,591,182,217.68 from ¥2,505,833,682.05, an increase of approximately 3.4%[27]. Shareholder Information - The largest shareholder, Guangdong Guanghui Investment Co., holds 42.60% of the shares, totaling 101,088,000 shares[11]. - Lin Peiqing, a natural person, holds 9.09% of the shares, amounting to 21,565,440 shares, with 16,848,000 shares being his own and 4,717,400 shares held in trust[11]. - Chen Qiong, another natural person, owns 5.54% of the shares, which is 13,141,440 shares, with 3,285,360 shares released from restrictions this period[14]. - The company has implemented a 2025 restricted stock incentive plan, which was approved on January 10, 2023[15]. - The total number of restricted shares at the end of the period is 39,569,828 shares, after 3,327,676 shares were released this period[14]. - The company has a total of 41,496,504 restricted shares at the beginning of the period, with 1,401,000 shares added this period[14]. - The company’s actual controllers are Lin Peiqing and Chen Qiong, who are married[11]. - The shareholding structure indicates significant control by a few key individuals and entities, with the top 10 shareholders holding substantial stakes[11]. Financial Expenses and Investments - Financial expenses increased by 38.46% to CNY 22,265,559.88, primarily due to higher interest expenses[7]. - The company plans to invest up to $40 million in building a production base in Thailand to enhance its global supply chain and competitiveness[21]. - Cash outflow for employee compensation was $249.48 million, up from $216.34 million in the previous period[33]. - The company received tax refunds totaling $12.12 million, compared to $6.43 million in the prior year[33]. Other Financial Metrics - The weighted average return on equity slightly decreased to 2.70% from 2.73% year-on-year[3]. - The company reported a decrease in research and development expenses to ¥29,103,485.10 from ¥30,794,385.11, a reduction of approximately 5.5%[29]. - The company received government subsidies amounting to CNY 1,183,139.40, which positively impacted its financial performance[4]. - Other comprehensive income after tax for the current period was ¥13,655,659.94, a recovery from a loss of ¥26,692,941.41 in the previous period[30].

为充分尊重投资者、提升交流的针对性，现就公司 2024 年度和 2025 年第一 季度业绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投 资者可于 2025 年 4 月 25 日（星期五）15:30 前访问 http://ir.p5w.net/zj/，或扫描 下方二维码，进入问题征集专题页面。公司将通过本次业绩说明会，在信息披露 允许范围内就投资者普遍关注的问题进行回答。 1 | 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-046 | | --- | --- | --- | | 证券代码：123113 | 证券简称：仙乐转债 | | 仙乐健康科技股份有限公司 关于举行 2024 年度暨 2025 年第一季度 网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 18 日 披露了《2024 年年度报告》和《2024 年年度报告摘要》，已于 2025 年 4 月 24 日 披露了《2025 年第一季度报告》。为便于广大投资者更深入全面 ...

仙乐健康科技股份有限公司 | 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-044 | | --- | --- | --- | | 证券代码：123113 | 证券简称：仙乐转债 | | 董事会 仙乐健康科技股份有限公司 二〇二五年四月二十四日 2025 年第一季度报告披露提示性公告 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司（以下简称"公司"）董事会于 2025 年 4 月 22 日召开第四届董事会第九次会议，审议通过了公司《2025 年第一季度报告》；公 司监事会于 2025 年 4 月 22 日召开第四届监事会第七次会议，审议通过了公司 《2025 年第一季度报告》。 为使投资者全面了解公司 2025 年第一季度的经营成果和财务状况，公司 《2025 年第一季度报告》于 2025 年 4 月 24 日在中国证监会指定的创业板信息 披露网站上披露，敬请投资者注意查阅。 特此公告。 ...

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-043 | | --- | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | | 仙乐健康科技股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 仙乐健康科技股份有限公司（以下简称"公司"）于 2025 年 4 月 22 日以通 讯会议方式召开第四届监事会第七次会议。会议通知根据《仙乐健康科技股份有 限公司监事会议事规则》第十二条规定于 2025 年 4 月 20 日以电子邮件、微信信 息等方式送达给全体监事，召集人谢盈瑜女士已在本次会议上作出说明。本次会 议由监事会主席谢盈瑜女士召集和主持，应到监事 3 人，实到监事 3 人。本次会 议的召集、召开符合《中华人民共和国公司法》（以下简称"《公司法》"）《中华 人民共和国证券法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》《仙乐健康科技股份 有限公司章程》（以下简称"《公司章 ...

经与会董事认真审议，本次会议以回收表决票的表决方式逐项表决通过了以 下决议： 1、审议通过了《2025 年第一季度报告》 第四届董事会第九次会议决议公告 | 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-042 | | --- | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | | 经审议，董事会认为：公司编制《2025 年第一季度报告》的程序符合法律、 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司 一、 董事会会议召开情况 仙乐健康科技股份有限公司（以下简称"公司"）第四届董事会第九次会议 于 2025 年 4 月 22 日以通讯会议方式召开。会议通知根据《仙乐健康科技股份有 限公司董事会议事规则》第十一条规定于 2025 年 4 月 20 日以电子邮件、微信信 息等方式送达给全体董事及其他列席人员，召集人林培青先生已在本次会议上作 出说明。本次会议由董事长林培青先生召集和主持，应出席董事 7 人，实际出席 董事 7 人。公司监事、高级管理人员列席本次会议。本次会议的召集、 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The overall performance in 2024 is in line with expectations, with a stable start for the new retail business and anticipation for incremental growth [7] - The company expects a compound annual growth rate (CAGR) of 23.64% for net profit over the past three years, excluding BF [7] - The revenue for 2024 is projected to be 4.21 billion yuan, with a year-on-year growth of 17.56% [7] - The net profit attributable to the parent company for 2024 is expected to be 325.06 million yuan, reflecting a year-on-year increase of 15.66% [7] - The company anticipates net profits of 391.89 million yuan, 496.65 million yuan, and 585.57 million yuan for 2025, 2026, and 2027 respectively, with growth rates of 20.56%, 26.73%, and 17.90% [7] Financial Summary - Total revenue for 2023 was 3.58 billion yuan, with a year-on-year increase of 42.87% [1] - The latest diluted EPS for 2024 is projected at 1.37 yuan per share, with a P/E ratio of 17.94 [1] - The gross profit margin for 2024 is expected to be 31.46%, an increase of 1.19 percentage points year-on-year [7] - The company’s total assets are projected to reach 5.49 billion yuan in 2024, with total liabilities of 2.85 billion yuan [8] - The cash flow from operating activities for 2024 is expected to be 567 million yuan [8]

Core Insights - Company reported a total revenue of 4.211 billion yuan for 2024, representing an 18% year-on-year increase, with a net profit of 325 million yuan, up 16% [1] - The fourth quarter of 2024 saw total revenue of 1.163 billion yuan, an 8% increase year-on-year, but a decline in net profit by 11% to 85 million yuan [1] Financial Performance - Gross margin increased by 1 percentage point to 31.46%, driven by cost reductions in procurement and optimized pricing strategies [2] - Sales and management expense ratios rose by 1 percentage point and 0.1 percentage points to 8.39% and 9.92%, respectively, due to sales team upgrades and marketing promotions [2] - Net profit margin slightly decreased by 0.01 percentage points to 6.70%, remaining relatively stable [2] Business Segments - Revenue from soft capsules reached 1.984 billion yuan, a 30% increase, attributed to product innovation and operational optimization, along with contributions from BF for external growth [3] - Revenue from gummy products was 995 million yuan, up 35%, mainly due to market expansion in the Americas and the establishment of BF gummy business [3] Market Expansion - Revenue in the China region decreased by 10% to 1.661 billion yuan, with the company restructuring its sales team and establishing a new retail business development team to stabilize domestic operations [4] - Revenue in the Americas increased by 60% to 1.666 billion yuan, benefiting from scale effects and a strong order backlog [4] - European revenue reached 604 million yuan, a 14% increase, with the launch of automated packaging production lines improving local delivery times [4] Future Outlook - The company is expected to enhance profitability through integration and cost-reduction measures, with a positive long-term outlook on product innovation and strong market competitiveness [5] - Earnings per share (EPS) forecasts for 2025-2027 are projected at 1.73, 2.23, and 2.70 yuan, with corresponding price-to-earnings (PE) ratios of 14, 11, and 9 times [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's overall performance in 2024 is in line with expectations, with a stable start in the new retail business and anticipation for growth [7] - The company is expected to achieve a net profit of 3.92 billion, 4.97 billion, and 5.86 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 20.56%, 26.73%, and 17.90% [7] Financial Performance Summary - Total revenue for 2023 was 3,582 million yuan, projected to grow to 4,211 million yuan in 2024, representing a year-on-year increase of 17.56% [1] - The net profit attributable to the parent company for 2023 was 281.04 million yuan, expected to rise to 325.06 million yuan in 2024, reflecting a year-on-year growth of 15.66% [1] - The latest diluted EPS for 2023 was 1.18 yuan, projected to increase to 1.37 yuan in 2024 [1] - The company's P/E ratio is expected to decrease from 20.75 in 2023 to 17.94 in 2024, indicating improved valuation [1] Revenue Breakdown - Revenue from the new retail business is expected to stabilize, with domestic market challenges anticipated in 2024, but a recovery is expected in early 2025 [7] - The overseas market's revenue share increased by 12 percentage points to 61%, surpassing domestic revenue [7] - The product structure shows a significant increase in revenue from gummies, which grew by 34.54% year-on-year, while other traditional forms like tablets and powders saw declines [7] Cost and Margin Analysis - The gross margin for 2024 is projected at 31.46%, an increase of 1.19 percentage points year-on-year, attributed to digital transformation and cost optimization [7] - Sales expenses are expected to rise due to team upgrades and marketing efforts, while the overall net profit margin remains stable at 6.7% [7]

证券代码：300791 证券简称：仙乐健康 公告编码：2025-029 证券代码：123113 证券简称：仙乐转债 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 德勤华永会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：标准的无保留意见。 公司本年度会计师事务所为德勤华永会计师事务所（特殊普通合伙）。 非标准审计意见提示 □适用 √不适用 公司上市时未盈利且目前未实现盈利 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 公司经本次董事会审议通过的利润分配预案为：以实施权益分派股权登记日登记的总股本扣除公司回购 专用证券账户上已回购股份后的股本为基数，向全体股东每10股派发现金红利6.5元（含税），送红股0 股（含税），以资本公积金向全体股东每10股转增3股。 二、公司基本情况 1、公司简介 1、公司业务概况： 公司是全球领先的营养健康食品合同研发生产商，围绕"创新科技"和"国际化"两大战略，致力于为全球 营养健康 ...